134575-11-4

Usage

Uses

Used in Organic Synthesis:
((1R,5S,6S)-3-Benzyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-carbamic acid tert-butyl ester is utilized as a synthetic intermediate for the creation of various organic compounds. Its unique bicyclic structure and functional groups make it a valuable building block in the synthesis of complex organic molecules.
Used in Drug Development:
In the pharmaceutical industry, ((1R,5S,6S)-3-Benzyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-carbamic acid tert-butyl ester is employed as a precursor in the development of new drugs. Its specific structural features may contribute to the design of innovative therapeutic agents with novel mechanisms of action.
It is crucial to exercise caution and adhere to proper safety measures when handling and utilizing this chemical, given its potential toxicity and reactivity.

Upstream product

• 134575-06-7 ethyl (1α,5α,6α)-3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylate 
• 134575-07-8 (1α,5α,6α)-6-hydroxymethyl-3-benzyl-3-aza-bicyclo[3.1.0]hexane 
• 134575-08-9 [1α,5α,6α]-3-Benzyl-3-azabicyclo[3.1.0]hexane-6-carboxaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 134575-10-3 [1α,5α,6α]-6-Aminomethyl-3-benzyl-3-azabicyclo[3.1.0]hexane 

Downstream Products

• 925457-09-6 1-(2,4-difluorophenyl)-7-[(1α,5α,6α)-6-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 134575-12-5 (1α,5α,6α)-6-(tert-butoxycarbonyl)aminomethylene-3-azabicyclo[3.1.0]hexane 

Relevant academic research and scientific papers

CANNABINOID RECEPTOR LIGANDS

Compounds of Formula (I) and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective asCB2 receptor ligands in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.

Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.

The synthesis of four new computer-designed fluoroquinolones which have been predicted by QSAR analysis to be active against the protozoa Toxoplasma gondii is described. These compounds are inhibitory in vitro for T. gondii. One of these compounds has a remarkably high activity comparable to that of trovafloxacin. It combines the basic cyclopropyl-quinoline structure of gatifloxacin or moxifloxacin with the C-7 6-amino-3-azabicyclo[3.1.0]hexyl side chain of trovafloxacin. The four compounds are also inhibitory for blood stages of Plasmodium falciparum though at high concentration. These results confirm the potential of quinolones as anti-T. gondii and antimalarial drugs but also show that the QSAR models for T. gondii cannot be reliably extended for screening antimalarial activity.